Clinical Trials Planned in 2006
FRANKLIN, Mass., June 28 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (Nasdaq: SONT) announced today the formation of a Clinical
Advisory Board who will provide product and clinical guidance to the Company
for the continuous non-invasive glucose monitor that is being developed for
use in intensive care units (ICU) and operating rooms (OR).
Appointments to the Clinical Advisory Board include:
* Bruce R. Bistrian, M.D., Ph.D., Chief of Clinical Nutrition, Beth Israel
Deaconess Medical Center and Professor, Harvard Medical School.
* Peter A. Burke, M.D., Chief of Critical Care Section, Surgery, Boston
Medical Center, and Associate Professor of Surgery, Boston University
School of Medicine.
* Alan Lisbon, M.D., Vice Chairman of Critical Care, Beth Israel Deaconess
Medical Center and Associate Professor, Anesthesiology, Harvard Medical
School.
* Mitchell M. Levy, M.D., Medical Director, Medical Intensive Care Unit,
Rhode Island Hospital
* Stanley A. Nasraway, M.D., Chief of Surgical Critical Care, Tufts-New
England Medical Center, and Associate Professor, Tufts Medical School.
* Richard J. Shemin, M.D., Chief of the Department of Cardiothoracic
Surgery, Boston Medical Center and Professor and Chairman of the
Department of Cardiothoracic Surgery, Boston University School of
Medicine.
"We are privileged to have attracted such a preeminent group of critical
care physicians from New England's top research and teaching hospitals to
serve as an advisory board for our continuous non-invasive glucose monitor,"
stated Sontra's Chief Executive Officer and President, Thomas W. Davison,
Ph.D. "This product has the potential to meet a major unmet need in
critically ill and post surgical patients for continuous non-invasive glucose
monitoring. We are developing a product for the $5 billion home testing
market in parallel with the critical care monitor."
Dr. Stanley A. Nasraway stated, "Tight glycemic control for ICU patients
has been shown in clinical studies to improve outcomes by reducing mortality
and complications related to infection, thereby decreasing hospital stay and
cost. This is achieved today with intensive insulin therapy and hourly blood
glucose measurements, the importance of which is quickly emerging as a Vital
Sign. A continuous non-invasive glucose monitor will not only save valuable
nursing time by avoiding the requirement for frequent needle stick glucose
measurements but will provide the information we need to develop better
control algorithms for insulin administration."
A primary cause of infection in critically ill patients is hyperglycemia
which is a result of insulin resistance and total parenteral nutrition.
Numerous clinical studies have demonstrated that intensive insulin therapy to
maintain tight glycemic control significantly reduces infection rates,
mortality, hospital stay and cost. As a result, intensive insulin
administration with frequent blood glucose testing is a recent trend in
critical care medicine for patients with and without diabetes. Today,
standard practice by ICU nurses is to measure blood glucose at the bedside
hourly and to note, not only the absolute value, but the rate of change. A
continuous non-invasive glucose monitor should reduce the increasing workload
for critical care nurses who spend an estimated 5 - 10 minutes per hour
managing intensive insulin therapy with repeated blood glucose measurements.
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a technology leader in transdermal science.
Sontra's SonoPrep ultrasound-mediated skin permeation technology combined with
technical competencies in transdermal drug formulation, delivery systems and
biosensors is creating a new paradigm in transdermal drug delivery and
diagnosis. The enabling potential of SonoPrep technology has been
demonstrated in clinical trials at leading universities and medical centers
for topical delivery of vaccines, transdermal delivery of large molecular
weight drugs and continuous non-invasive glucose monitoring. Sontra is
currently marketing the SonoPrep device and procedure tray for use with
topical lidocaine to achieve rapid (within five minutes) skin anesthesia.
SonoPrep is a registered trademark of Sontra Medical Corporation. All
other company, product or service names mentioned herein are the trademarks or
registered trademarks of their respective owners.
This press release contains forward-looking statements, which address a
variety of subjects including, for example, the expected development schedule,
benefits, efficacy and market opportunity of the Sontra's glucose monitor in
the critical care environment, and Sontra's business, research, product
development, regulatory approval, marketing and distribution plans and
strategies. Statements that are not historical facts, including statements
about our beliefs and expectations, are forward-looking statements. Such
statements are based on our current expectations and are subject to a number
of factors and uncertainties, which could cause actual results to differ
materially from those described in the forward-looking statements. The
following important factors and uncertainties, among others, could cause
actual results to differ materially from those described in these forward-
looking statements: adverse results in product development, clinical trials,
commercialization efforts, product distribution and market acceptance;
difficulties or delays in obtaining regulatory approvals to market products
resulting from development efforts; failure to obtain and maintain patent
protection for discoveries; commercial limitations imposed by patents owned or
controlled by third parties; dependence upon strategic partners and third-
party distributors to develop, commercialize, market and sell products based
on our work; the commercial success of products; and the requirement for
substantial funding to conduct research and development and to expand
commercialization, distribution and marketing activities. For detailed
information about factors that could cause actual results to differ materially
from those described in the forward-looking statements, please refer to
Sontra's filings with the Securities and Exchange Commission, including
Sontra's most recent Quarterly Report on Form 10-QSB. Forward-looking
statements represent management's current expectations and are inherently
uncertain. We do not undertake any obligation to update forward-looking
statements made by us.
Contacts:
Sean Moran, Sontra Medical CFO or Evan Smith, CFA / Erica Pettit
508-530-0334 Financial Dynamics
212-850-5606 / 212-850-5614
SOURCE Sontra Medical Corporation
 back to top
Related links:
http://www.sontra.com
CONTACT:
Sean Moran, Sontra Medical CFO,
+1-508-530-0334; or Evan Smith, CFA, +1-212-850-5606, or Erica
Pettit, +1-212-850-5614 both of Financial Dynamics
|
